Baff/april inhibitors
Baff/april inhibitors has been studied in 2 papers since 2026: none in people yet, 2 reviews; 2 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 26, 2026: “IgA nephropathy: evolving pathogenic concepts and emerging targeted therapies”.
2 papers study it1 findingUpdated
1 new paper in 30 daysSee all 2 papers on baff/april inhibitors
What did studies of baff/april inhibitors find?
1Studies of baff/april inhibitors measured one outcome, proteinuria.
Proteinuria
downin reviews1
1 study
Proteinuria
downin reviews1
Baff/april inhibitors decrease proteinuria (IgA nephropathy).
“Late-stage inhibitors targeting B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) substantially reduce Gd-IgA1 and proteinuria.”
ReviewIgA nephropathy
IgA nephropathy: evolving pathogenic concepts and emerging targeted therapies
Human immunology
Latest
2 papers in 12 monthsBMC Nephrology
Efficacy and safety of supportive and immunosuppressive therapies in the treatment of lgA nephropathy: a network Meta-analysis of randomized clinical trials
Meta-analysis of randomized trialsIgA nephropathy